Singulex, Inc. announced that it has entered into a strategic collaboration with QIAGEN N.V. Through the collaboration, QIAGEN will have access to Singulex's Single Molecule Counting immunodiagnostic platform, adding additional immunoassay capabilities to QIAGEN's existing molecular testing services for the development of companion diagnostics. Additionally, QIAGEN will have access to Singulex's CLIA-licensed laboratory. Singulex will provide QIAGEN with access to its proprietary SMCTM immunodiagnostics platform, and the companies intend to collaborate in a range of disease applications.